Defining a correlate of protection for chikungunya virus vaccines

Gregg N. Milligan, Barbara S. Schnierle, Alexander J. McAuley, David W.C. Beasley

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Chikungunya virus infection causes a debilitating febrile illness that in many affected individuals is associated with long-term sequelae that can persist for months or years. Over the past decade a large number of candidate vaccines have been developed, several of which have now entered clinical trials. The rapid and sporadic nature of chikungunya outbreaks poses challenges for planning of large clinical efficacy trials suggesting that licensure of chikungunya vaccines may utilize non-traditional approval pathways based on identification of immunological endpoint(s) predictive of clinical benefit. This report reviews the current status of nonclinical and clinical testing and potential challenges for defining a suitable surrogate or correlate of protection.

Original languageEnglish (US)
Pages (from-to)7427-7436
Number of pages10
JournalVaccine
Volume37
Issue number50
DOIs
StatePublished - Nov 28 2019

    Fingerprint

Keywords

  • Animal models
  • Arbovirus
  • Assays
  • Clinical trial
  • Neutralizing antibodies
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this